Rosch shares drop after profit warning
This article was originally published in Clinica
Executive Summary
German company Rosch Medizintechnik's shares lost more than a quarter of their value after the company lowered its earnings outlook for the full year. The company, which develops the INJEX needle-free injection system, attributed the poor results to the fact that German health insurers had not yet agreed to reimburse for the product. Shares in the company reached E13.55 ($11.50), a new 52-week low. This compares with a year-high of E68.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.